TABLE 3.
Pharmacological treatments in SSc patients studied
| Drug | CCB | PDE5-I | ERAs | Cilostazol | Pentoxifylline | PGA | PPIs | Prokinetics |
|---|---|---|---|---|---|---|---|---|
| Total SSc | 54 (65) | 24 (29) | 2 (2.4) | 12 (14.5) | 9 (10.8) | 0 (0) 58 | (69.9) | 5 (6) |
| dcSSc | 14 (82) | 7 (41) | 1 (6) | 2 (12) | 3 (18) | 0 (0) | 11 (65) | 0 (0) |
| lcSSc | 40 (62) | 16 (25) | 0 (0) | 10 (16) | 6 (9) | 0 (0) | 45 (70) | 5 (8) |
| Drug | GC | MTX | MFM/MFS | CYC | Azathiopine | D-Pen | Ig IV | bDMARs |
| Total SSc | 11 (13) | 11 (13) | 3 (3.6) | 1 (1.2) | 5 (6) | 4 (4.8) | 0 (0) | 0 (0) |
| dcSSc | 4 (23) | 6 (35) | 2 (12) | 1 (6) | 1 (6) | 1 (6) | 0 (0) | 0 (0) |
| lcSSc | 6 (9) | 5 (8) | 1 (2) | 0 (0) | 3 (5) | 3 (5) | 0 (0) | 0 (0) |
Data are expressed as n (%). The numbers of dcSSC + lcSSC may differ from total SSc as patients with ssSSc (n=2) are not shown. CCB, calcium channel blockers; PDE5-I, phosphodiesterase 5 inhibitors; ERAs, endothelin receptor antagonists; PGA, prostaglandin analogs; PPIs, proton pump inhibitors; GC, glucocorticoids; MTX, methotrexate; MFM, mycophenolate mofetil/MFS, mycophenolate sodium; CYC, cyclophosphamide; D-Pen, D-penicillamine; IV Ig, intravenous immunoglobulins; bDMARS, biological disease-modifying antirheumatic drugs. IT, immunosuppresive treatment.